Phase I trial: PXL 272092
Latest Information Update: 25 Jul 2022
Price :
$35 *
At a glance
- Drugs PXL 272092 (Primary)
- Indications Unspecified
- Focus Therapeutic Use
- Sponsors Hansa Biopharma AB
- 25 Jul 2022 Status changed from active, no longer recruiting to not yet recruiting.
- 27 May 2022 New trial record